Raquel C Maia

Summary

Affiliation: Rio de Janeiro
Country: Brazil

Publications

  1. doi An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation
    Raquel Ciuvalschi Maia
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil Serviço de Hematologia, Hospital do Cancer I, INCA, RJ, Brazil Electronic address
    Blood Cells Mol Dis 55:347-50. 2015
  2. ncbi NFkB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
    Fernanda Costas C de Faria
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Praça da Cruz Vermelha, 23, 6 and 186 andar Instituto Nacional de Cancer INCA, Rio de Janeiro, Brazil, CEP 20230 130
    Anticancer Agents Med Chem 15:345-52. 2015
  3. pmc The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia
    Gabriela Nestal de Moraes
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Praça da Cruz Vermelha 23, 6 andar, Centro, 20230 130 Rio de Janeiro, RJ, Brazil
    Leuk Res Treatment 2012:671702. 2012
  4. doi LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells
    Raquel C Maia
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil
    Invest New Drugs 29:1143-55. 2011
  5. doi Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells
    Eduardo J S Salustiano
    Laboratório de Imunologia Tumoral, Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Invest New Drugs 28:139-44. 2010
  6. doi Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels
    Gabriela Nestal de Moraes
    Cellular and Molecular Hemato Oncology Laboratory, Program of Molecular Hemato Oncology, Brazilian National Cancer Institute INCA, Praça da Cruz Vermelha, 23 6 andar, Rio de Janeiro, Brazil
    Eur J Cell Biol 92:247-56. 2013
  7. ncbi The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells
    Flaviana R de Souza Reis
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil
    Anticancer Agents Med Chem 13:341-51. 2013
  8. doi Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia
    Flaviana R S Reis
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Câncer Rio de Janeiro, RJ, Brazil
    Oncol Rep 26:471-8. 2011
  9. doi FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance
    Gabriela Nestal de Moraes
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Praça da Cruz Vermelha, 23 6 andar, Centro, 20230 130 Rio de Janeiro, Brazil Department of Surgery and Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine ICTEM, Du Cane Road, London W12 0NN, UK
    Cell Signal 27:2496-505. 2015
  10. doi Immunodetection of caspase-3 by Western blot using glutaraldehyde
    Gabriela Nestal de Moraes
    Coordination of Clinical Research, Brazilian National Institute of Cancer, CEP 20231 050 Rio de Janeiro, RJ, Brazil
    Anal Biochem 415:203-5. 2011

Collaborators

  • Eric W F Lam
  • Andre Luiz Mencalha
  • Gabriela Nestal de Moraes
  • Flavia C Vasconcelos
  • Paulo R R Costa
  • Karina L Silva
  • Fernanda Costas C de Faria
  • Paloma Silva de Souza
  • João P B Viola
  • Deborah Delbue
  • Flaviana R de Souza Reis
  • Cinthya Sternberg
  • Carolina P Castro
  • Flaviana R S Reis
  • Camilla de S B Veiga
  • Eduardo J S Salustiano
  • Vivian M Rumjanek
  • Stefania Zona
  • Lídia M Magalhães
  • Susanne Crocamo
  • Paula Sabbo Bernardo
  • Maria Eduarda Bento Leal
  • Pasarat Khongkow
  • Marcela Cristina Robaina
  • Ana R Gomes
  • Andre L S Cruz
  • Reinaldo D Bello
  • Flavia da Cunha Vasconcelos
  • Paloma S de Souza
  • Alcides J da Silva
  • Giuliana P Mognol
  • Fernanda C Casal de Faria
  • Flaviana Ruade Souza Reis
  • Paloma Silva Souza
  • Fernanda Casal de Faria Costas
  • Flavia Cunha Vasconcelos
  • Erika Carvalho
  • Cláudia J B P Coelho
  • Arthur Moellman-Coelho
  • Eliana Abdelhay
  • Tatiana C Carneiro-Lobo
  • Aline F Ferreira
  • Débora L Pereira
  • Silvia M F Carvalho
  • Robson Q Monteiro
  • Fabíola A Castro
  • Renata F Fernandes
  • Chaquip D Netto
  • Thiago S Bacelar
  • Alcides J M da Silva
  • Camilla D Buarque
  • Geraldo B Cavalcanti
  • Ernesto de Meis
  • Jolie K Kwee

Detail Information

Publications13

  1. doi An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation
    Raquel Ciuvalschi Maia
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Coordenação de Pesquisa, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil Serviço de Hematologia, Hospital do Cancer I, INCA, RJ, Brazil Electronic address
    Blood Cells Mol Dis 55:347-50. 2015
    ..To the best of our knowledge, this is the first reported case of severe PMF with JAK2 mutation in a child. We provide evidence that a better quality of life and long survival in pediatric PMF may be provided by splenectomy...
  2. ncbi NFkB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
    Fernanda Costas C de Faria
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Praça da Cruz Vermelha, 23, 6 and 186 andar Instituto Nacional de Cancer INCA, Rio de Janeiro, Brazil, CEP 20230 130
    Anticancer Agents Med Chem 15:345-52. 2015
    ....
  3. pmc The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia
    Gabriela Nestal de Moraes
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Praça da Cruz Vermelha 23, 6 andar, Centro, 20230 130 Rio de Janeiro, RJ, Brazil
    Leuk Res Treatment 2012:671702. 2012
    ..We focus on the potential role of the influx and efflux transporters, the inhibitor of apoptosis proteins, and transcription factor-mediated signals as feasible molecular targets to overcome the development of TKIs resistance in CML...
  4. doi LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells
    Raquel C Maia
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil
    Invest New Drugs 29:1143-55. 2011
    ..The data suggest that LQB-118 has a potent anti-CML activity that can overcome multifactorial drug resistance mechanisms, making this compound a promising new anti-CML agent...
  5. doi Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells
    Eduardo J S Salustiano
    Laboratório de Imunologia Tumoral, Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    Invest New Drugs 28:139-44. 2010
    ..In contrast, lapachol (2) and beta-lapachone (3), which cannot be bioactivated by reduction, showed little activity against the same cell lines...
  6. doi Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels
    Gabriela Nestal de Moraes
    Cellular and Molecular Hemato Oncology Laboratory, Program of Molecular Hemato Oncology, Brazilian National Cancer Institute INCA, Praça da Cruz Vermelha, 23 6 andar, Rio de Janeiro, Brazil
    Eur J Cell Biol 92:247-56. 2013
    ..Also, our findings suggest that dox-mediated modulation of Survivin and XIAP might sensitize cells to taxanes when used in a sequential regimen. ..
  7. ncbi The therapeutical potential of a novel pterocarpanquinone LQB-118 to target inhibitor of apoptosis proteins in acute myeloid leukemia cells
    Flaviana R de Souza Reis
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Rio de Janeiro, RJ, Brazil
    Anticancer Agents Med Chem 13:341-51. 2013
    ..Our findings suggest that LQB-118 might be a promising therapeutic approach for AML patients through survivin downregulation...
  8. doi Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia
    Flaviana R S Reis
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Pesquisa em Hemato Oncologia Molecular, Instituto Nacional de Câncer Rio de Janeiro, RJ, Brazil
    Oncol Rep 26:471-8. 2011
    ..018), but not in early (p=0.5) chronic phase of CML, suggests that this association may play a biological role in late CML phase and may offer an important target for the development of new therapies...
  9. doi FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance
    Gabriela Nestal de Moraes
    Laboratório de Hemato Oncologia Celular e Molecular, Programa de Hemato Oncologia Molecular, Instituto Nacional de Cancer INCA, Praça da Cruz Vermelha, 23 6 andar, Centro, 20230 130 Rio de Janeiro, Brazil Department of Surgery and Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine ICTEM, Du Cane Road, London W12 0NN, UK
    Cell Signal 27:2496-505. 2015
    ..Together, these findings suggest that the overexpression of FOXM1, XIAP, and Survivin contributes to the development of drug-resistance and is associated with poor clinical outcome in breast cancer patients. ..
  10. doi Immunodetection of caspase-3 by Western blot using glutaraldehyde
    Gabriela Nestal de Moraes
    Coordination of Clinical Research, Brazilian National Institute of Cancer, CEP 20231 050 Rio de Janeiro, RJ, Brazil
    Anal Biochem 415:203-5. 2011
    ..Here we present a modification of the Western blot protocol to improve sensitivity of caspase-3 detection, providing a valuable tool to access its activation in biological specimens...
  11. doi Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias
    Camilla de S B Veiga
    Instituto de Bioquimica Medica, Universidade Federal do Rio de Janeiro, RJ, Brazil
    Blood Cells Mol Dis 46:230-4. 2011
    ..We conclude that PAR-1 might play an important biological role in aggressive leukemias and might offer additional strategies for the development of new therapies...
  12. pmc Microparticles induce multifactorial resistance through oncogenic pathways independently of cancer cell type
    Paloma Silva de Souza
    Program of Hemato Oncology Molecular, Brazilian National Cancer Institute, Rio de Janeiro, Brazil
    Cancer Sci 106:60-8. 2015
    ..In addition, MP promoted microRNA transfer and NFκB and Yb-1 activation. Therefore, our results indicate that MP can induce a multifactorial phenotype in sensitive cancer cells. ..
  13. ncbi Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice
    Flavia C Vasconcelos
    Laboratório de Hematologia Celular e Molecular, Servico de Hematologia, Hospital do Câncer HC I, Instituto Nacional de Cancer INCA, Rio de Janeiro RJ, Brazil
    Leuk Res 31:445-54. 2007
    ..000). Similarly, MRP1 positive cells were best detected by Rho-123 as opposed to DiOC(2) (p=0.007). Our results support the idea that Rho-123 is the substrate of choice for leukemic cells...